| FSLR |
Report |
Q2 2026 Adjusted EBITDA |
BEAT |
pred ~$530M vs. cons ~$455M (implied midpoint of $400-500M co. guide) |
MEDIUM |
| FSLR |
Report |
Q2 2026 Non-GAAP Diluted EPS |
BEAT |
pred ~$3.05 vs. cons ~$2.80 |
MEDIUM |
| FSLR |
Report |
Q2 2026 Net Sales/Revenue |
IN-LINE |
pred ~$1.07B vs. cons ~$1.06B |
MEDIUM |
| FSLR |
Guide |
FY2026 Net Sales Guidance |
UNCHANGED |
guide ~$5.05B (reiterate $4.9-5.2B range) vs. cons $5.1B (FY2026) |
MEDIUM |
| FSLR |
Guide |
FY2026 Adjusted EBITDA Guidance |
UNCHANGED |
guide ~$2.7B (reiterate $2.6-2.8B range) vs. cons ~$2.68B (FY2026) |
MEDIUM |
| FSLR |
Guide |
Contracted Backlog (GW/$B) |
BETTER |
guide ~49GW/$14.7B vs. prior-quarter base 47.9GW/$14.4B (as of Q2 2026) |
LOW |
| FSLR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
LOW |
| FSLR |
Return |
5-day cumulative residual |
+0.5% (FADE) |
FSLR has beaten its own EBITDA guide range in each of the last several quarters and enters this print heavily oversold (down ~36% from the June high) with sell-side targets far above the current price, setting up a likely relief bounce on a Q2 beat-and-reiterate. But follow-through is unlikely: the Section 232 polysilicon ruling remains unresolved into early August and becomes the next binary catalyst, the securities litigation overhang (lead-plaintiff deadline Aug 24) keeps a lid on re-rating, and OBBBA/FEOC sourcing ambiguity plus heavy reliance on 45X credits (~75% of gross margin per Bernstein's bear case) make analysts cautious about raising FY27 out-year estimates even after an in-line-to-better Q2, so early gains should fade as the market re-focuses on unresolved policy risk and a technically damaged chart. |
LOW |